Parkinson's Disease: Follow‐up After “Drug Holiday”

The Journal of Clinical Pharmacology

Volumn 26, Issue 8, 1986, Pages 662-667

  Feldman, Robert G ^a   Kaye, Jeffrey A ^a   Lannon, Margaret C ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA; LEVODOPA;

ADVERSE DRUG REACTION; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONFUSION; DRUG DEPRIVATION; DRUG DOSE; DRUG THERAPY; DYSKINESIA; HALLUCINATION; HUMAN; INTOXICATION; NERVOUS SYSTEM; NEUROTOXICITY; ON OFF PHENOMENON; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; THERAPY;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMAN; LEVODOPA; MALE; MIDDLE AGE; PARKINSON DISEASE; SUPPORT, NON-U.S. GOV'T;

EID: 0023028759     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1986.tb02969.x     Document Type: Article

References (26)

1. Fluctuations in disability in Parkinson's disease—clinical aspects
2. Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment
3. Should levodopa therapy be started early or late?
4. Dopamine receptors in the Parkinsonian brain
5. Neurotransmitter receptor alterations in Parkinson's disease
6. Does 0‐methyldopa play a role in levodopa‐induced dyskinesias?
7. O‐methyldopa interferes with striatal utilization of levodopa
8. Pre‐synaptic subsensitivity as a possible basis for sensitization by long‐term dopamine minetics
9. Receptor basis for dopaminergic supersensitivity in Parkinson's disease
10. The L‐dopa on‐off effect in Parkinson disease: Treatment by transient withdrawal and dopamine receptor resensitization
11. Effects of L‐dopa metabolites at a dopamine receptor suggest a basis for “on‐off” effect in Parkinson disease
12. Clinical studies of carbidopa and L‐DOPA in the treatment of Parkinson's disease
13. Parkinsonism: Onset, progression and mortality
14. Parkinson's disease and related disturbances
15. L‐DOPA decarboxylation in chronically treated patients
16. Neuroleptic malignant‐like syndrome due to L‐DOPA therapy withdrawal
17. Enhanced response to low doses of levodopa after withdrawal from chronic treatment
18. Is L‐dopa drug holiday useful?
19. Drug holiday in the management of Parkinson's disease
20. Are levodopa “drug holidays” justified?
21. Chronic low‐dose levodopa therapy in Parkinson's disease: An argument for delaying levodopa therapy
22. Progression and prognosis in Parkinson's disease
23. Success and problems of long‐term levodopa therapy in Parkinson's disease
24. Reappraisal of temporary levodopa withdrawal (“drug holiday”) in Parkinson's disease
25. Temporary levodopa withdrawal (letter)
26. Successful management of Parkinson's disease following drug holiday (abstract)